Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.

Minev BR, Lander E, Feller JF, Berman M, Greenwood BM, Minev I, Santidrian AF, Nguyen D, Draganov D, Killinc MO, Vyalkova A, Kesari S, McClay E, Carabulea G, Marincola FM, Butterfield LH, Szalay AA.

J Transl Med. 2019 Aug 19;17(1):271. doi: 10.1186/s12967-019-2011-3.

2.

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I.

J Immunother Cancer. 2019 Aug 15;7(1):221. doi: 10.1186/s40425-019-0683-0. Review.

3.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

4.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

5.

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM.

J Immunother Cancer. 2019 Apr 24;7(1):113. doi: 10.1186/s40425-019-0552-x.

6.

Tumor-Derived α-Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells.

Santos PM, Menk AV, Shi J, Tsung A, Delgoffe GM, Butterfield LH.

Cancer Immunol Res. 2019 Jun;7(6):1001-1012. doi: 10.1158/2326-6066.CIR-18-0513. Epub 2019 Apr 15.

PMID:
30988028
7.

Interleukin 32 expression in human melanoma.

Paz H, Tsoi J, Kalbasi A, Grasso CS, McBride WH, Schaue D, Butterfield LH, Maurer DM, Ribas A, Graeber TG, Economou JS.

J Transl Med. 2019 Apr 5;17(1):113. doi: 10.1186/s12967-019-1862-y.

8.

Melanoma vaccines: clinical status and immune endpoints.

Maurer DM, Butterfield LH, Vujanovic L.

Melanoma Res. 2019 Apr;29(2):109-118. doi: 10.1097/CMR.0000000000000535.

PMID:
30802228
9.

CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α.

Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A, Huang A, Kirkwood JM, Butterfield LH.

Front Immunol. 2019 Jan 29;10:14. doi: 10.3389/fimmu.2019.00014. eCollection 2019.

10.

SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.

Butterfield LH, Disis ML, Fox BA, Kaufman DR, Khleif SN, Wang E; Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers.

J Immunother Cancer. 2018 Dec 4;6(1):138. doi: 10.1186/s40425-018-0453-4. Review.

11.

Next Steps for Immune Checkpoints in Hepatocellular Carcinoma.

Santos PM, Butterfield LH.

Gastroenterology. 2018 Dec;155(6):1684-1686. doi: 10.1053/j.gastro.2018.11.008. Epub 2018 Nov 9. No abstract available.

PMID:
30419214
12.

Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells.

Li C, Song B, Santos PM, Butterfield LH.

Cell Immunol. 2019 Jan;335:59-67. doi: 10.1016/j.cellimm.2018.10.011. Epub 2018 Nov 1.

PMID:
30392891
13.

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.

Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM.

Cancer. 2018 Nov 15;124(22):4332-4341. doi: 10.1002/cncr.31734. Epub 2018 Oct 10.

PMID:
30303516
14.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

15.

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.

Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, Tarhini AA.

J Transl Med. 2018 Jul 4;16(1):184. doi: 10.1186/s12967-018-1563-y.

16.

Immune oncology, immune responsiveness and the theory of everything.

Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa J.

J Immunother Cancer. 2018 Jun 5;6(1):50. doi: 10.1186/s40425-018-0355-5.

17.

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi.

Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM.

Cancer Prev Res (Phila). 2018 Jul;11(7):429-438. doi: 10.1158/1940-6207.CAPR-17-0268. Epub 2018 Apr 24.

18.

Prospective Analyses of Cytokine Mediation of Sleep and Survival in the Context of Advanced Cancer.

Steel JL, Terhorst L, Collins KP, Geller DA, Vodovotz Y, Kim J, Krane A, Antoni M, Marsh JW, Burke LE, Butterfield LH, Penedo FJ, Buysse DJ, Tsung A.

Psychosom Med. 2018 Jun;80(5):483-491. doi: 10.1097/PSY.0000000000000579.

19.

Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.

Müller S, Agnihotri S, Shoger KE, Myers MI, Smith N, Chaparala S, Villanueva CR, Chattopadhyay A, Lee AV, Butterfield LH, Diaz A, Okada H, Pollack IF, Kohanbash G.

JCI Insight. 2018 Apr 5;3(7). pii: 98791. doi: 10.1172/jci.insight.98791. eCollection 2018 Apr 5.

20.

Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.

Geskin LJ, Damiano JJ, Patrone CC, Butterfield LH, Kirkwood JM, Falo LD.

Melanoma Res. 2018 Jun;28(3):211-221. doi: 10.1097/CMR.0000000000000441.

PMID:
29543704
21.

Dendritic Cell-Based Cancer Vaccines.

Santos PM, Butterfield LH.

J Immunol. 2018 Jan 15;200(2):443-449. doi: 10.4049/jimmunol.1701024. Review.

22.

High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation.

Zahorchak AF, Macedo C, Hamm DE, Butterfield LH, Metes DM, Thomson AW.

Cell Immunol. 2018 Jan;323:9-18. doi: 10.1016/j.cellimm.2017.08.008. Epub 2017 Sep 14.

23.

Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.

Geskin LJ, Akilov OE, Kwon S, Schowalter M, Watkins S, Whiteside TL, Butterfield LH, Falo LD Jr.

Cancer Immunol Immunother. 2018 Mar;67(3):423-434. doi: 10.1007/s00262-017-2090-z. Epub 2017 Dec 4.

PMID:
29204699
24.

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.

Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA.

J Transl Med. 2017 Nov 3;15(1):223. doi: 10.1186/s12967-017-1325-2.

25.

Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus.

Guo ZS, Liu Z, Sathaiah M, Wang J, Ravindranathan R, Kim E, Huang S, Kenniston TW, Bell JC, Zeh HJ 3rd, Butterfield LH, Gambotto A, Bartlett DL.

Mol Ther Methods Clin Dev. 2017 Sep 30;7:112-122. doi: 10.1016/j.omtm.2017.09.007. eCollection 2017 Dec 15.

26.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S.

Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Erratum in: Lancet Oncol. 2018 Jan;19(1):e8.

PMID:
28988646
27.

The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.

Butterfield LH.

Semin Cancer Biol. 2018 Oct;52(Pt 2):12-15. doi: 10.1016/j.semcancer.2017.09.006. Epub 2017 Sep 22. Review.

PMID:
28943324
28.

Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL.

Cytotherapy. 2017 Oct;19(10):1225-1232. doi: 10.1016/j.jcyt.2017.07.008. Epub 2017 Aug 30.

PMID:
28864289
29.

Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.

Gulley JL, Repasky EA, Wood LS, Butterfield LH.

J Immunother Cancer. 2017 Jul 18;5(1):55. doi: 10.1186/s40425-017-0262-1. Review.

30.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

31.

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).

Butterfield LH, Zhao F, Lee S, Tarhini AA, Margolin KA, White RL, Atkins MB, Cohen GI, Whiteside TL, Kirkwood JM, Lawson DH.

Clin Cancer Res. 2017 Sep 1;23(17):5034-5043. doi: 10.1158/1078-0432.CCR-16-3016. Epub 2017 May 23.

32.

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS.

Cancer Immunol Res. 2017 Jun;5(6):480-492. doi: 10.1158/2326-6066.CIR-16-0329. Epub 2017 May 18.

33.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

34.

Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death.

Vujanovic L, Stahl EC, Pardee AD, Geller DA, Tsung A, Watkins SC, Gibson GA, Storkus WJ, Butterfield LH.

Cancer Immunol Res. 2017 Jun;5(6):493-502. doi: 10.1158/2326-6066.CIR-16-0216. Epub 2017 May 3.

35.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

36.

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.

Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA.

J Transl Med. 2017 Feb 21;15(1):39. doi: 10.1186/s12967-017-1140-9.

37.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

38.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.

Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:76. eCollection 2016. Review.

39.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.

Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ, Zhang J, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:77. doi: 10.1186/s40425-016-0179-0. eCollection 2016. Review.

40.

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H.

J Neurooncol. 2016 Dec;130(3):517-527. Epub 2016 Sep 13.

41.

Cancer immunotherapy trials: leading a paradigm shift in drug development.

Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM, Kaufman HL.

J Immunother Cancer. 2016 Jul 19;4:42. doi: 10.1186/s40425-016-0146-9. eCollection 2016. No abstract available.

42.

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.

Retseck J, VanderWeele R, Lin HM, Lin Y, Butterfield LH, Tarhini AA.

J Immunother Cancer. 2016 Jun 21;4:38. doi: 10.1186/s40425-016-0141-1. eCollection 2016.

43.

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.

Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Galon J, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM.

J Immunother Cancer. 2016 Jun 21;4:37. doi: 10.1186/s40425-016-0142-0. eCollection 2016.

44.

Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer.

Radomski M, Zeh HJ, Edington HD, Pingpank JF, Butterfield LH, Whiteside TL, Wieckowski E, Bartlett DL, Kalinski P.

J Immunother Cancer. 2016 Apr 19;4:24. doi: 10.1186/s40425-016-0128-y. eCollection 2016.

45.

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H.

Neuro Oncol. 2016 Aug;18(8):1157-68. doi: 10.1093/neuonc/now026. Epub 2016 Mar 15.

46.

Web-based collaborative care intervention to manage cancer-related symptoms in the palliative care setting.

Steel JL, Geller DA, Kim KH, Butterfield LH, Spring M, Grady J, Sun W, Marsh W, Antoni M, Dew MA, Helgeson V, Schulz R, Tsung A.

Cancer. 2016 Apr 15;122(8):1270-82. doi: 10.1002/cncr.29906. Epub 2016 Mar 11.

47.

Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation.

Thomson AW, Zahorchak AF, Ezzelarab MB, Butterfield LH, Lakkis FG, Metes DM.

Front Immunol. 2016 Jan 28;7:15. doi: 10.3389/fimmu.2016.00015. eCollection 2016. Review.

48.

Lessons learned from cancer vaccine trials and target antigen choice.

Butterfield LH.

Cancer Immunol Immunother. 2016 Jul;65(7):805-12. doi: 10.1007/s00262-016-1801-1. Epub 2016 Feb 3. Review.

49.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

50.

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.

Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, Kirkwood JM.

J Immunother Cancer. 2015 Sep 15;3:39. doi: 10.1186/s40425-015-0081-1. eCollection 2015.

Supplemental Content

Loading ...
Support Center